HGEN Humanigen
- 0.000
- 0.0000.00%
Humanigen News
COVID Pick Humanigen Files for Bankruptcy
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.08%
Sector Update: Health Care Stocks Steady Tuesday Afternoon
Health care stocks were little changed Tuesday afternoon, with the NYSE Health Care Index fractionally higher and the Health Care Select Sector SPDR Fund (XLV) down nearly 0.1%. The iShares Biotechnol
Sector Update: Health Care
Health care stocks were steady Tuesday afternoon, with the NYSE Health Care Index down nearly 0.1% and the Health Care Select Sector SPDR Fund (XLV) almost flat. The iShares Biotechnology ETF (IBB) wa
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersBullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 33.8% to $4.63 during Tuesday's regular session. Trading volume for Bullfrog AI Hldgs's stock is 42.6 million as of 13:30 EST. This is 84
Stocks That Hit 52-Week Lows On Tuesday
 On Tuesday, 56 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS)
Humanigen Issues 'Going Concern' Warning; Shares Hit 52-Week Low
Humanigen (HGEN) said Tuesday it expects that it will not be able to continue as a going concern and is exploring all restructuring options. The options include a possible bankruptcy or other insolven
Humanigen Shares Plunge 73% as Business Combination Fails, Going Concern Issues Raised
By Adam L. Cataldo Humanigen shares dropped after a proposed business combination fell through and the company said it may be forced to cease operations and file for bankruptcy, according to a U.S. S
Humanigen (NASDAQ:HGEN) Nosedives With Bankruptcy Looming Large
Humanigen to Weigh Bankruptcy as Shares Delist From Nasdaq
Humanigen Said It Anticipates That It Will Not Be Able To Continue As A Going Concern And Is Exploring All Restructuring Options, Including Bankruptcy
Humanigen Said It Anticipates That It Will Not Be Able To Continue As A Going Concern And Is Exploring All Restructuring Options, Including Bankruptcy
Humanigen HGEN Delist and Restructuring; Biotricity BTCY AI Deal With Google & Amazon
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersEvelo Biosciences (NASDAQ:EVLO) shares rose 320.3% to $0.35 during Friday's pre-market session. The company's market cap stands at $39.0 million. Surface Oncology (NASDAQ:SURF) shares moved upw
Humanigen Granted U.S. Patent Titled 'METHOD OF INCREASING THE EFFICACY OF CAR-T IMMUNOTHERAPY USING LENZILUMAB'
Humanigen Granted U.S. Patent Titled 'METHOD OF INCREASING THE EFFICACY OF CAR-T IMMUNOTHERAPY USING LENZILUMAB'
Humanigen Presents Promising New Hematologic Data From PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response
Short Interest in Humanigen, Inc. (NASDAQ:HGEN) Decreases By 8.3%
Humanigen, Inc. (NASDAQ:HGEN – Get Rating) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 5,820,000 shares, a decrease of 8.3%
Humanigen (NASDAQ:HGEN) Stock Price Up 3.7%
Humanigen, Inc. (NASDAQ:HGEN – Get Rating) shares rose 3.7% during trading on Tuesday . The stock traded as high as $0.17 and last traded at $0.17. Approximately 1,205,421 shares were traded during t
On April 18, 2023, Humanigen Was Notified That It Had Been Granted An Extension Until August 21, 2023 By Nasdaq To Demonstrate Compliance With All Applicable Requirements For Listing Of The Company's Common Stock
On April 18, 2023, Humanigen Was Notified That It Had Been Granted An Extension Until August 21, 2023 By Nasdaq To Demonstrate Compliance With All Applicable Requirements For Listing Of The Company's
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Analysis
Price Target
No Data
